Tag: CBD

January 15, 2020

Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada

Dalton Pharma Services, has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada.
December 18, 2019

Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor

Cardiol Therapeutics Inc. is pleased to announce that it has appointed Michael J. Willner, Esq. as Business Advisor to the...
December 3, 2019

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to Its Board of Directors

Cardiol Therapeutics Inc. is pleased to announce the appointment of Mr. Colin Stott to its Board of Directors, effective immediately.
November 27, 2019

Cannabis Industry Leaders Call for CBD Testing and Regulation

Diligent CBD testing and oversight could be the key to sustained industry growth and consumer health in North American cannabis.
November 25, 2019

Cardiol Therapeutics Comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

Cardiol Therapeutics Inc. commented on Purisys, LLC's news release issued on November 21st.
November 19, 2019

Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100

Cardiol Therapeutics Inc. is pleased to announce the formation of the Clinical Steering Committee for a Phase 2 international trial.
October 1, 2019

Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100

Cardiol Therapeutics Inc., announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation.